Study of Lisaftoclax (APG-2575) Single Agent and Combination With Therapy in Patients Relapsed/Refractory AML
A phase 1/2 trial of Azacitidine, Olverembatinib in acute myeloid leukaemia, run by Ascentage Pharma Group Inc., now recruiting.
Overview
Study of Lisaftoclax (APG-2575) Single Agent and Combination With Therapy in Patients Relapsed/Refractory AML is a phase 1/2 interventional study registered as NCT04501120 by Ascentage Pharma Group Inc., with 682 participants planned, started 2020-09-28 and due to reach its primary completion in 2028-09. Interventions recorded: Lisaftoclax (APG-2575), Reduced-dose HHT, standard-dose HHT, Azacitidine, Lisaftoclax (APG-2575). Conditions listed: Relapsed/Refractory Acute Myeloid Leukaemia, Myeloid Malignancy. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Study of Olverembatinib in Patients With Newly Diagnosed Ph+ ALL (POLARIS-1)
Shares Olverembatinib, Ascentage Pharma.
- TrialStudy of Olverembatinib (HQP1351) in Patients With CML-CP
Shares Olverembatinib, Ascentage Pharma.
- TrialA Study of Olverembatinib in SDH-deficient GIST.
Shares Olverembatinib, Ascentage Pharma.
- TrialA Pivotal Study of APG-2575 (Lisaftoclax) Combined With Azacitidine in the Treatment of Acute Myeloid Leukemia
Shares Ascentage Pharma, Azacitidine, Acute myeloid leukaemia.
- TrialA Study to Assess the Safety and Efficacy of Two Combinations of Isocitrate Dehydrogenase (IDH) Mutant Targeted Therapies Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) Harboring IDH Mutations Who Are Not Candidates to Receive Intensive Induction Chemotherapy
Shares Azacitidine, Acute myeloid leukaemia.
- TrialA Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Best Supportive Care as Maintenance Therapy in Japanese Participants With Acute Myeloid Leukemia (AML) in Complete Remission
Shares Azacitidine, Acute myeloid leukaemia.
- TrialA Phase 2 Study of MAX-40279 Combined With Venetoclax and Azacitidine in Unfit Newly Diagnosed Acute Myeloid Leukemia
Shares Azacitidine, Acute myeloid leukaemia.
- TrialAn Open-label Phase 3b Study of Ivosidenib in Combination With Azacitidine in Adult Patients Newly Diagnosed With IDH1m Acute Myeloid Leukemia (AML) Ineligible for Intensive Induction Chemotherapy.
Shares Azacitidine, Acute myeloid leukaemia.